Micrin Peptide Segmentation for Organ Mass Inhibition

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current understanding of organ size control is complex and lacks a general inhibitory mechanism, with known influences being mostly stimulatory or specific, whereas a general inhibitor of organ mass, 'micrin', has been identified but its chemical nature and functional peptides remain unclear.

Innovation Solution

Development of physiologically active peptides and antibodies targeting micrin or its fragments, specifically a polypeptide with a sequence of up to 20 amino acids, including a preferred sequence M K P L T G K V K E F N N I, which are believed to be fragments of micrin, and their use in compositions and therapeutic applications.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If impure preparations of sheep ovarian venous plasma are used to identify micrin, then organ mass reduction effect is demonstrated, but the chemical nature and sequence information of micrin remains unknown

Engineering Contradiction:
Improveorgan mass reduction effectVSAvoidchemical nature of micrin
Core Design Contradiction:
ReliabilityVSLoss of information

Solution Approach 1:

The micrin polypeptide (7000-8000 Da) is segmented into smaller active fragments (1400-2500 Da) containing 14-20 amino acids. This segmentation allows identification of the minimal active sequence while maintaining the organ mass reduction effect, resolving the contradiction between demonstrating efficacy and identifying chemical structure.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The active micrin sequence is extracted from the complex impure plasma preparation through purification and sequencing. The specific amino acid sequence MKPLTGKVKEFNNI is isolated and characterized, extracting the essential information from the crude preparation that demonstrated the biological effect.

Inventive Principle:
Principle #2Taking out (Extraction)

2Productivity

If known molecular influences such as growth hormone and IGF1 are used to control organ size, then stimulatory effects are achieved, but general inhibitory control mechanism is lacking

Engineering Contradiction:
Improveorgan growth controlVSAvoidinhibitory mechanism
Core Design Contradiction:
ProductivityVSAdaptability or versatility

Solution Approach 1:

Instead of using stimulatory factors (growth hormone, IGF1) to control organ size, the invention uses micrin, an inhibitory factor that works in the opposite direction. This inversion provides the missing general inhibitory mechanism to balance the known stimulatory pathways for comprehensive organ size control.

Inventive Principle:
Principle #13The other way round (Inversion)

3Reliability

If micrin polypeptide with molecular weight 7000-8000 Da is identified, then general inhibitor of organ mass is found, but the functional active motifs and minimal active sequence are unclear

Engineering Contradiction:
Improvegeneral inhibitor of organ massVSAvoidfunctional active motifs
Core Design Contradiction:
ReliabilityVSManufacturing precision

Solution Approach 1:

The 7000-8000 Da micrin polypeptide is segmented into smaller fragments of 1400-2500 Da containing 14-20 amino acids. This segmentation identifies the minimal active sequence (such as MKPLTGKVKEFNNI) that contains the functional motifs responsible for organ mass inhibition, providing precise manufacturing targets while maintaining the reliable inhibitory effect.

Inventive Principle:
Principle #1Segmentation

Data Source

PatentEP2234632B1Proteinaceous compounds
Publication Date: 2014.10.29 ENDOCRINE PHARMA
  • EP2234632B1 patent drawingFigure 1
  • EP2234632B1 patent drawingFigure 2
  • EP2234632B1 patent drawingFigure 3

AI summary

A purified novel peptide micrin and its fragments are disclosed. The molecule has hormonal functions and has wide-ranging biological effects. Several uses are disclosed including its therapeutic potential in tissue reduction, tumour suppression, infertility and senescence. A micrin-recognising antibody and the micrin gene are also disclosed.